Lacklustre Performance Is Driving Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Low P/S
Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
Capitulation in Biotech Is Near, as Well as a Rally – Piper Sandler
Entrada Therapeutics Presents New Data Supporting Its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society
Capricor Stock Rallies 20% on DMD Data Presentation Update
Express News | Entrada Therapeutics Promotes Natarajan Sethuraman, Phd, to President of Research and Development
Press Release: Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development
Āshibio Announces Appointment of Dipal Doshi, CEO of Entrada Therapeutics, to Its Board of Directors
Entrada Therapeutics Price Target Maintained With a $25.00/Share by Oppenheimer
Oppenheimer Reiterates Outperform on Entrada Therapeutics, Maintains $25 Price Target
Oppenheimer Initiates Entrada Therapeutics(TRDA.US) With Buy Rating, Announces Target Price $25
Oppenheimer analyst Francois Brisebois initiates coverage on $Entrada Therapeutics(TRDA.US)$ with a buy rating, and sets the target price at $25.According to TipRanks data, the analyst has a success
Entrada Therapeutics Inc (TRDA) Gets a Buy From Oppenheimer
Entrada Therapeutics Insider Sold Shares Worth $440,801, According to a Recent SEC Filing
Forecast: Analysts Think Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Business Prospects Have Improved Drastically
H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Maintains Target Price $18
H.C. Wainwright analyst Ram Selvaraju maintains $Entrada Therapeutics(TRDA.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 4
HC Wainwright & Co. Reiterates Buy on Entrada Therapeutics, Maintains $18 Price Target
Entrada Therapeutics Analyst Ratings
Buy Rating Affirmed for Entrada Therapeutics on Strong Clinical Trial Data and Regulatory Prospects
TD Cowen Maintains Entrada Therapeutics(TRDA.US) With Buy Rating
TD Cowen analyst Joseph Thome maintains $Entrada Therapeutics(TRDA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 41.5% and a total average return of -1.9% over
TD Cowen Keeps Their Buy Rating on Entrada Therapeutics Inc (TRDA)